Key clinical point: TP53 structural rearrangements are frequent in metastatic prostatic carcinoma.
Major finding: In TP53 structural rearrangements, there was a loss of p53 protein expression by immunohistochemistry; and in the 8 TP53-rearranged cases, concurrent PTEN loss was identified in 4 cases, TMPRSS2-ERG fusion in 5 cases, and AR and FOXA1 amplification in 1 case each.
Study details: Clinical cases of 926 tumors, solid and hematopoietic, were submitted for sequencing from 2015 - 2017 were reviewed, along with TP53 alterations identified across all cases of prostate carcinomas sequenced.
Sirohi D, et al. PLoS One. 2019 Jun 19;14(6):e0218618. doi: 10.1371/journal.pone.0218618.